- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2044-5385
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Resistance to targeted therapies: delving into FLT3 and IDH ; volume:12 ; number:6 ; day:9 ; month:6 ; year:2022 ; pages:1-8 ; date:6.2022
Blood cancer journal ; 12, Heft 6 (9.6.2022), 1-8, 6.2022
- Urheber
-
Desikan, Sai Prasad
Daver, Naval
DiNardo, Courtney
Kadia, Tapan
Konopleva, Marina
Ravandi, Farhad
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-022-00687-5
- URN
-
urn:nbn:de:101:1-2022080608004830218254
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:36 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Desikan, Sai Prasad
- Daver, Naval
- DiNardo, Courtney
- Kadia, Tapan
- Konopleva, Marina
- Ravandi, Farhad
- SpringerLink (Online service)
Ähnliche Objekte (12)
Therapies for IDH-Mutant Gliomas
Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
Evolution of resistance to MAPK-targeted therapies
Resistance to targeted therapies in acute myeloid leukemia
Targeted therapies for cancer
The importance of being CAFs (in cancer resistance to targeted therapies)
"Targeted therapies" beim nichtkleinzelligen Bronchialkarzinom
Targeted therapies for myeloproliferative neoplasms
Targeted Therapies in Pediatric Oncology
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
IDH
Therapies for IDH-Mutant Gliomas
Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
Evolution of resistance to MAPK-targeted therapies
Resistance to targeted therapies in acute myeloid leukemia
Targeted therapies for cancer
The importance of being CAFs (in cancer resistance to targeted therapies)
"Targeted therapies" beim nichtkleinzelligen Bronchialkarzinom
Targeted therapies for myeloproliferative neoplasms
Targeted Therapies in Pediatric Oncology
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
IDH
Therapies for IDH-Mutant Gliomas
Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
Evolution of resistance to MAPK-targeted therapies
Resistance to targeted therapies in acute myeloid leukemia
Targeted therapies for cancer
The importance of being CAFs (in cancer resistance to targeted therapies)
"Targeted therapies" beim nichtkleinzelligen Bronchialkarzinom
Targeted therapies for myeloproliferative neoplasms
Targeted Therapies in Pediatric Oncology
CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML